Matinas BioPharma Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK BASED COMPENSATION (Tables)

STOCK BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The Company recognized stock-based compensation expense in its consolidated statements of operations as follows ($ in thousands):

	$ in thousands
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2014		2013		2014		2013

Research and Development	$	223	$	27	$	330	$	27
General and Administrative		677		151		1,117		151
Total	$	900	$	178	$	1,447	$	178

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

The following table contains information about the Company’s stock plan at September 30, 2014:

	Awards Reserved			Awards
	for	Awards		Available
	Issuance	Issued		for Grant
2013 Equity Compensation Plan	8,250,000	5,582,650	*	2,667,350

* includes both stock grants and option grants

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the Company’s stock option activity and related information for the period from December 31, 2013 to September 30, 2014:

		Weighted average
	Number of Options	Exercise Price
Outstanding at December 31, 2013	3,160,000	$	0.94
Granted	2,380,000	$	1.23
Exercised	0		N/A
Forfeited	(100,918)	$	0.94
Expired	(24,082)	$	0.94
Outstanding at September 30, 2014	5,415,000	$	1.07

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References + Details